TNGX · ISSUER CIK 1819133
Tango Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 2 Tango Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $2.2M of sales on SEC Form 4.
↗2 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 4 of 4 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$2.2MInsider selling
−$2.2MNet open-market
Oct 5, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 5, 202617:36 | Oct 1, 2026 | TNGX | President, R&D | S · Sell10b5-1 | $24.47 | −27,000 | 115,743 | -19% | −$661K | ||
| Oct 5, 202617:36 | Oct 1, 2026 | TNGX | President, R&D | M · Exercise10b5-1 | $5.20 | +27,000 | 142,743 | +23% | $140K | ||
| Sep 24, 202619:41 | Sep 22, 2026 | TNGX | Principal Accounting Officer | S · Sell10b5-1 | $24.22 | −8,200 | 59,121 | -12% | −$199K | ||
| Sep 3, 202616:01 | Sep 1, 2026 | TNGX | President, R&D | S · Sell10b5-1 | $22.37 | −27,000 | 115,743 | -19% | −$604K | ||
| Sep 3, 202616:01 | Sep 1, 2026 | TNGX | President, R&D | M · Exercise10b5-1 | $5.20 | +27,000 | 142,743 | +23% | $140K | ||
| Aug 5, 202616:01 | Aug 3, 2026 | TNGX | President, R&D | S · Sell10b5-1 | $27.24 | −27,000 | 115,743 | -19% | −$736K | ||
| Aug 5, 202616:01 | Aug 3, 2026 | TNGX | President, R&D | M · Exercise10b5-1 | $5.20 | +27,000 | 142,743 | +23% | $140K |